Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.655 USD | +0.91% | -5.68% | +6.49% |
Financials (USD)
Sales 2024 * | 103M | Sales 2025 * | 76.06M | Capitalization | 128M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -50M | EV / Sales 2024 * | 1.24 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.68 x |
P/E ratio 2024 * |
-11.6
x | P/E ratio 2025 * |
-3.47
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -1.80% | ||
1 week | -3.53% | ||
Current month | -3.53% | ||
1 month | -19.61% | ||
3 months | -34.40% | ||
6 months | +11.56% | ||
Current year | +5.81% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 1.655 | +0.91% | 277 297 |
24-06-07 | 1.64 | -1.80% | 1,176,629 |
24-06-06 | 1.67 | 0.00% | 3,511,847 |
24-06-05 | 1.67 | -0.60% | 2,103,372 |
24-06-04 | 1.68 | -4.00% | 1,619,818 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.81% | 128M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.87% | 22.78B | |
-10.74% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- CTMX Stock